Eli Lilly and Company (LLY) Friday said that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Omvoh for the treatment of adults with active Crohn's disease.
The positive opinion was based on data from the Phase 3 VIVID-1 study in which patients treated with Omvoh achieved statistically significant improvement on the study's main goals compared to those on placebo.
Lilly has submitted marketing applications for Omvoh in Crohn's disease around the globe, including the U.S. and Japan. Decisions are expected from these regulatory authorities starting in the first half of 2025.
Omvoh is already approved for the treatment of ulcerative colitis in more than 40 countries.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.